April 28 The U.S. Food and Drug Administration on Friday approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia (AML).
AML is a rapidly progressing cancer, which forms in the bone marrow and results in an increased number of white blood cells in the bloodstream.
Rydapt has secured approval for adults with newly diagnosed AML that have a specific genetic mutation called FLT3, in combination with chemotherapy, the FDA said. (Reporting by Natalie Grover in Bengaluru)
PRESS DIGEST- British Business - May 30
May 30 The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
UPDATE 5-Key projects at risk as Greens back NDP in British Columbia
VANCOUVER, May 29 British Columbia's minority Green Party on Monday struck a deal with the left-leaning New Democrats to govern Canada's western-most province, a move that casts doubt on the future of key energy projects from firms such as Kinder Morgan Inc.